Compared with other breast cancer subtypes, TNBC exhibits stronger immunogenicity, abundant tumor-infiltrating lymphocytes (TILs), higher programmed cell death ligand 1 (PD-L1) expression and tumor mutation burden (TMB) (2, 11, 12), numerous explorations on adding ICIs to the therapeutic arsenal of TNBC have acquired inspiring feedback (13–15). The gene discussed is CD274; the disease is neoplasm.